New Radio-DARPin Therapy for Lung Cancer Enters Early Human Trials

Molecular Partners and Orano Med have started dosing patients in a Phase 1/2a clinical trial for MP0712, an experimental therapy targeting small cell lung cancer and other neuroendocrine tumors. This investigational drug uses a Radio-DARPin approach with lead-212 to target specific cancer cells.